The CJC-1295 / Ipamorelin Stack: Two Pathways to Growth Hormone
The combination of CJC-1295 and Ipamorelin represents one of the most studied growth hormone (GH) secretagogue pairings in peptide research. These two compounds stimulate GH release through distinct receptor pathways — GHRH and ghrelin receptors respectively — creating a complementary mechanism that published research suggests produces greater GH elevation than either compound alone.
This guide reviews the published science behind each compound, the rationale for combination protocols, and the practical considerations for researchers working with this stack.
CJC-1295: The GHRH Analog
Molecular Profile
- Classification: Growth Hormone Releasing Hormone (GHRH) analog
- Sequence basis: Modified form of GHRH(1-29)
- Key modifications: Four amino acid substitutions for increased stability
- Variants: CJC-1295 (no DAC) and CJC-1295 DAC (with Drug Affinity Complex)
CJC-1295 Without DAC (Modified GRF 1-29)
- Half-life: ~30 minutes
- Mechanism: Binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and release
- GH release pattern: Pulsatile — mimics natural GH release rhythm
- Administration frequency: Multiple times daily in published research
CJC-1295 With DAC
- Half-life: ~6-8 days
- Mechanism: Same GHRH receptor binding, but the Drug Affinity Complex (DAC) forms a covalent bond with circulating albumin
- GH release pattern: Sustained elevation — less pulsatile than the non-DAC form
- Administration frequency: Once or twice weekly in published research
Published Research: CJC-1295
Teichman et al. (2006) published a dose-escalation study in the Journal of Clinical Endocrinology & Metabolism demonstrating that CJC-1295 DAC produced sustained GH and IGF-1 elevation in healthy subjects. A single injection of CJC-1295 DAC elevated GH levels for 6+ days and IGF-1 for 9-11 days.
The study reported mean GH levels increased 2- to 10-fold and IGF-1 levels increased 1.5- to 3-fold from baseline, with dose-dependent responses.
Ipamorelin: The Selective Ghrelin Agonist
Molecular Profile
- Classification: Growth Hormone Secretagogue (GHS) / Ghrelin receptor agonist
- Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2 (pentapeptide)
- Molecular weight: ~711.85 Da
- Half-life: ~2 hours
- Selectivity: Highly selective for GH release — minimal effects on cortisol, prolactin, and ACTH
Mechanism of Action
Ipamorelin binds to the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. This receptor is distinct from the GHRH receptor — providing a separate, additive pathway for GH stimulation.
Why Ipamorelin Is "Selective"
Unlike earlier ghrelin receptor agonists (GHRP-6, GHRP-2, hexarelin), Ipamorelin demonstrates minimal stimulation of cortisol, aldosterone, prolactin, and ACTH at GH-releasing doses. This selectivity has made it the preferred GHS for research protocols where minimizing off-target hormonal effects is important.
Raun et al. (1998) published the initial characterization in European Journal of Endocrinology, demonstrating Ipamorelin's selective GH release profile in animal models — potent GH stimulation without the cortisol and prolactin elevation seen with GHRP-6.
GH Release Profile
Anderson et al. (2001) conducted a human pharmacokinetic study showing that Ipamorelin produced dose-dependent GH release with peak levels at approximately 40 minutes post-injection. The GH response was clean — no significant changes in cortisol or other pituitary hormones.
The Rationale for Combination
The CJC-1295 + Ipamorelin stack is based on complementary receptor targeting:
| Property | CJC-1295 | Ipamorelin |
|---|---|---|
| Receptor target | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Mechanism | Stimulates GH synthesis & release | Amplifies GH pulse release |
| Effect on IGF-1 | Direct elevation | Indirect (via GH elevation) |
| Cortisol effect | Minimal | Minimal (selective) |
| Release pattern | Sustained GH elevation | Acute GH pulse |
Synergistic GH Release
Published research on GHRH + GHRP combinations has consistently demonstrated that combining a GHRH analog with a ghrelin receptor agonist produces GH release that is greater than the sum of either compound used alone. This synergy is attributed to the dual-receptor activation — GHRH primarily increases the amplitude of GH pulses, while ghrelin agonists increase pulse frequency.
Bowers et al. (1990) established the synergistic principle in early GHRH + GHRP research, and subsequent studies have confirmed the effect across multiple GHRH/GHRP pairings.
Protocol Design Considerations
DAC vs. Non-DAC CJC-1295
The choice between CJC-1295 variants affects protocol design:
- CJC-1295 (no DAC) + Ipamorelin: Both administered 2-3 times daily in published research. Produces more physiological, pulsatile GH release. Most commonly studied combination.
- CJC-1295 DAC + Ipamorelin: CJC-1295 DAC once weekly, Ipamorelin 2-3 times daily. The sustained GHRH activity from DAC combines with Ipamorelin's acute GH pulses. Less studied as a specific combination.
Timing Considerations
Published research protocols typically administer GH secretagogues during physiological GH release windows:
- Pre-sleep: Aligns with the largest natural GH pulse (first 90 minutes of sleep)
- Fasting state: GH release is potentiated in the fasted state; glucose and insulin blunt GH response
- Post-exercise: Exercise is itself a GH stimulus; post-exercise administration may augment the response
Published Safety Profile
Based on published clinical and preclinical data:
CJC-1295
Teichman et al. (2006) reported the most common adverse events as injection site reactions (redness, swelling) and transient flushing. No serious adverse events were attributed to CJC-1295 in the published trial data.
Ipamorelin
Published studies report a generally well-tolerated profile. Transient GI effects (increased appetite, mild nausea) have been noted at higher doses, consistent with ghrelin receptor activation. The absence of cortisol stimulation is a key safety advantage over less selective GHRPs.
IGF-1 and Downstream Effects
GH secretagogue research is ultimately about GH's downstream mediator, insulin-like growth factor 1 (IGF-1):
- GH stimulates hepatic IGF-1 production
- IGF-1 mediates many of GH's anabolic, metabolic, and cellular effects
- CJC-1295 has been shown to elevate IGF-1 for 9-11 days after a single injection
- The combination protocol produces sustained IGF-1 elevation through continuous GH stimulation
BeaCapra's Peak Stack
BeaCapra offers CJC-1295/Ipamorelin alongside Sermorelin as The Peak Stack — a comprehensive growth hormone secretagogue protocol bundle. Available with 20% subscribe-and-save savings on recurring delivery, matching the multi-week protocol timelines typical of GH secretagogue research.
Key Published References
- Teichman SL et al. "Prolonged stimulation of GH and IGF-1 secretion by CJC-1295." J Clin Endocrinol Metab. 2006;91(3):799-805.
- Raun K et al. "Ipamorelin, a new GH-releasing peptide with selectivity." Eur J Endocrinol. 1998;139(5):552-561.
- Anderson LL et al. "Ipamorelin effects on GH release in humans." Clinical pharmacology studies.
- Bowers CY et al. "On the actions of GH-releasing hexapeptide, GHRP." Endocrinology. 1990;128:2027-2035.
Frequently Asked Questions
Why combine CJC-1295 and Ipamorelin instead of using one alone?
The compounds work through different receptors (GHRH and ghrelin receptors). Published research shows that combining a GHRH analog with a ghrelin agonist produces synergistic GH release — greater than the sum of either used individually. CJC-1295 increases GH pulse amplitude while Ipamorelin increases pulse frequency.
Should I use CJC-1295 with or without DAC?
Without DAC: shorter half-life (~30 min), more pulsatile GH release, requires more frequent administration. With DAC: extended half-life (~6-8 days), sustained GH elevation, less frequent administration. The non-DAC form is more commonly combined with Ipamorelin in published research protocols.
Does Ipamorelin increase cortisol?
Published research consistently shows Ipamorelin has minimal effect on cortisol, ACTH, and prolactin at GH-releasing doses. This selectivity distinguishes it from earlier GHRPs like GHRP-6 and GHRP-2, which produce more off-target hormonal effects.
How long do CJC-1295/Ipamorelin protocols typically run?
Published research protocols range from 4 weeks to 6+ months. GH and IGF-1 reach steady state after approximately 4-5 weeks of consistent administration. BeaCapra's subscription model supports these extended timelines with automatic 30, 60, or 90-day delivery.